FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen to update the labeling. The change reflects an expanded or updated labeli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

SUPPL AP for BLINCYTO (BLINATUMOMAB)